

11/01/2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Dear Sir,


Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Ref: Aspira Pathlab & Diagnostics Limited
Scrip Code: 540788

Please find attached the disclosure pursuant to requirement of Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 in the prescribed format.

Please take it on your record.

Thanking you,
Yours faithfully,



Arvind Bhanushali
For and on behalf of promoters and Promoter group
Cc:
ASPIRA PATHLAB & DIAGNOSTICS LIMITED
Flat No. 2, R.D. Shah Bldg,
Shraddhanand Road Opp. Ghatkopar Railway Station,
Ghatkopar (West) Mumbai - 400086

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Aspira Pathlab & Diagnostics Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Promoters & Promoter Group Yashraj Biotechnology Ltd Arvind Bhanushali Deepali Bhanushali Paresh Bhanushali Geeta Bhanushali Bharat Dagha Raj Bhanushali (For detail shareholding refer Annexure 1)		
Whether the acquirer belongs to Promoter/Promoter group	YES		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	3731395	40.15 ^(S)	40.15 ^(S)
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	3731395	40.15^(S)	40.15^(S)
Details of acquisition/sale	Due to non-participation of the Promoters and Promoter Group in the preferential allotment of the Target Company, the aggregate percentage shareholding of the		

Arc


Promoters and Promoter Group decreased from 40.15% to 36.25%.

a) Shares carrying voting rights acquired/sold			
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/-d)	0	0	0.00
After the acquisition/sale, holding of:			
a) Shares carrying voting rights	3731395	36.25 ^(#)	36.22 ^(#)
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	3731395	36.25^(#)	36.22^(#)
Mode of acquisition / sale (e.g. open market / off-market /public issue / rights issue / preferential allotment / inter-se transfer etc).	Percentage of shareholding reduced due to Preferential allotment made to Non- Promoters		
Date of acquisition / sale of shares /VR-or date of receipt of intimation of allotment of shares, whichever is applicable	January 08, 2021		
Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 9,29,30,000/- divided into 92,93,000 equity shares of Rs. 10/- each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 10,29,30,000/- divided into 1,02,93,000 equity shares of Rs. 10/- each		

Ae

Total diluted share/voting capital of the TC after the said acquisition	Rs. 10,29,30,000/- divided into 1,02,93,000 equity shares of Rs. 10/- each

- (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.
- (\$) Percentage is calculated based on the entire paid-up capital of the TC before the preferential issue of Equity Shares.
- (#) Percentage is calculated based on the paid-up capital of the TC post preferential issue of Equity Shares.



Arvind Bhanushali
(on behalf of Promoter and Promoter Group)

Place: Mumbai

Date: January 11, 2021

Annexure 1

Details of Shareholding of Promoters/Person acting in concern ("PACs") for Aspira Pathlab & Diagnostics Limited

Name of Promoters/Promoter Group and Person Acting in Concern	No. of Equity Shares held before the preferential issue	% of shareholding before the preferential issue	No. of Equity Shares held after the preferential issue	% of Shareholding after the preferential issue
Yash Raj Biotechnolgy Limited	1435800	15.45	1435800	13.94
Arvind Karsandas Bhanushali	885500	9.53	885500	8.60
Deepali Arvind Bhanushali	885500	9.53	885500	8.60
Paresh Bhanji Bhanushali	260000	2.80	260000	2.52
Geeta Paresh Bhanushali	200000	2.15	200000	1.94
Bharat Tokarshi Dagha	60000	0.65	60000	0.58
Raj Arvind Bhanushali	4595	0.04	4595	0.04
Total Shares of Promoters, Promoter Group and Person acting in concern	3731395	40.15	3731395	36.22
Total paid-up Equity Shares of the Company	9293000		10293000	

Are